Belotero Volume (+) Lidocaine
Merz North America, Inc. · Decision date Nov 4, 2026
What did the FDA approve?
The FDA recorded an approval decision on 2026-11-04 for PMA supplement P250020/S004, submitted by Merz North America, Inc. under the Normal 180 Day Track. The supplement covers Belotero Volume (+) Lidocaine, a dermal implant for aesthetic use (product code LMH), within the general and plastic surgery specialty. The recorded supplement reason is a labeling change affecting indications, instructions, shelf life or tradename.
The stated scope is a change to the release specification and shelf-life specifications for the device. This is a supplement-level decision, not a new approval of the underlying system, and the source record does not describe the revised specification values, the affected shelf-life duration, or any labeling text. No supporting documents were included, so the specific technical content of the change cannot be verified from this record alone.
FDA approval order statement
approval for a change to the release specification and shelf-life specifications for Belotero Volume (+) Lidocaine (BVL) Dermal Filler
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Nov 4, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250020/S004
- Regulatory pathway
- PMA supplement
- Applicant
- Merz North America, Inc.
- Product code
- LMH
- Decision code
- APPR
- Decision date
- Nov 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
- Applicant
- Merz North America, Inc.
- Product code
- LMH
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250020. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250020 · Original PMA
Belotero Volume (+) Lidocaine
P250020/S004 received
Application receipt date recorded by FDA.
P250020/S005 · Related supplement
Belotero Volume (+) Lidocaine Dermal Filler
P250020/S004 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P250020. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250020
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Merz North America, Inc. | PMA approval | May 19, 2026 | FDA | |
Belotero Volume (+) Lidocaine Dermal FillerP250020/S005 | Merz North America, Inc. | PMA supplement | Sep 10, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
saypha ChiQP250021/S001 | Croma-Pharma GmbH | PMA supplement | Oct 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Merz North America, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6501 Six Forks Rd., Raleigh, NC, 27615
Sources and methodology
- Original FDA record: P250020/S004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



